Klonoff DC, et al. - In participants with type 1 diabetes (T1D), investigators tested the safety and effectiveness of fast-acting insulin aspart (faster aspart) vs insulin aspart (IAsp) used in continuous subcutaneous insulin infusion (CSII). According to results, faster aspart for baseline change in glycated hemoglobin was non-inferior to IAsp. Faster aspart provided a more effective and safer option for CSII treatment in T1D. No statistically significant difference was found in the overall rate of severe or blood glucose-confirmed hypoglycemia.